Educational Content Only: Not medical advice. Always consult a qualified healthcare provider before using any compounds. Many peptides are research chemicals not approved by the FDA.

hormones TrendingFDA Approved

Tesamorelin

Also known as: Egrifta, TH9507

GHRH analog — stimulates natural growth hormone release for visceral fat reduction

Method

injection

Level

intermediate

Risk

high

Status

FDA Approved

Quick Summary

GHRH analog — stimulates natural growth hormone release for visceral fat reduction

Also called: Egrifta, TH9507

What is Tesamorelin?

Tesamorelin is a 44-amino acid synthetic analogue of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce and release growth hormone in a pulsatile, physiological manner. It is the only FDA-approved treatment for HIV-associated lipodystrophy (excess visceral abdominal fat). Unlike exogenous HGH, tesamorelin preserves the body's natural GH feedback mechanisms and circadian rhythms, making it a more physiological approach to GH optimization.

How It's Made

Tesamorelin is produced via solid-phase peptide synthesis as a modified GHRH(1-44) analogue with a trans-3-hexenoic acid group attached to the tyrosine at position 1, which increases its stability and half-life compared to native GHRH.

Potential Benefits

18.2% visceral fat reduction at 26 weeks
117% IGF-1 increase
37% liver fat reduction (NAFLD improvement)
Preserves natural GH pulsatility
Improved body composition
Potential cognitive benefits

Who Uses This?

Common goals and use cases for Tesamorelin:

Visceral fat reductionGrowth hormone optimizationBody recompositionAnti-aging protocolsNAFLD managementCognitive enhancement

Where to Buy Tesamorelin

Affiliate links — use code for discount. Always consult a healthcare provider before use.

Want a personalized protocol?

Take our AI-powered quiz to get a peptide protocol tailored to your specific goals and health profile.